about
Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women.Clinical pharmacokinetics and pharmacodynamics of linagliptin.Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetesEffect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying.Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate.Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254.Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects.Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetesLinagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tabletsRelative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
P50
Q34630545-64AC99A0-08E1-445A-9EB9-A9AAB72C8CEAQ34638128-9149D9C8-78EB-4B81-9665-50F6306A6F22Q35800419-74872725-6DD6-40A9-81B0-6EC3E33BE0EDQ37161909-A3D6B501-42B1-4325-8411-14FFE37DBA8EQ37227407-D511E5AE-62A9-4D04-AFF8-E7545AF4CEA1Q42656227-7940E90A-70E7-4760-91B8-96861A156EC3Q43433454-A8CE68F8-DAA1-4BF3-B7B3-9948AAD42082Q46517057-189DBFB1-15CF-4B11-9340-CD0AB97A6D2AQ51444165-795A730E-BDE9-465F-B375-971C06A2AA41Q52808106-9CADE801-B35C-48EE-9DB2-7F30D09C3B33Q52874192-BD661A75-6E7B-488B-BE96-5F5B245505BDQ53468088-68BA8CF6-896D-42A9-B1A0-58B18FF034F9Q86122041-110242F0-BF03-4A41-A398-E4EB0CD7B800Q87730179-E6C8EE20-EB0F-46BA-ADE5-F78FE6F5799BQ95499734-31204876-79B4-4226-9DD0-A0F89136A7D3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
C Friedrich
@en
C Friedrich
@nl
type
label
C Friedrich
@en
C Friedrich
@nl
prefLabel
C Friedrich
@en
C Friedrich
@nl
P31
P496
0000-0001-8955-4808